Chemycal has been acquired by 3E
Learn MoreChemycal has been acquired by 3E
Learn More
Discover how Chemycal PRO helps you boosting your regulatory monitoring:
The U.S. Food and Drug Administration is warning patients and health care professionals of risks associated with the use of unapproved or unauthorized devices for diabetes management, including continuous glucose monitoring systems, insulin pumps and automated insulin dosing systems. In the safety communication issued today, the agency noted that the use of unapproved or unauthorized devices could result in inaccurate blood glucose (sugar) measurements or unsafe insulin dosing, which can lead to injury requiring medical intervention or even death.
CONTINUE READING ON www.fda.gov
2013 © MyChemicalMonitoring. ALL Rights Reserved. About Us | Terms and Conditions
